Evidence review
The Edit, Checked but Not Graded: $209 Semaglutide, $309 Tirzepatide
The Edit publishes a GLP-1 ladder whose every prepay division checks out — and a headline price that is a first-order promo. What our August 2026 pass found.
On this page
The Scorecard's #1 pick
CoreAge Rx
A−91.8Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Check availability- Semaglutide
- $149/mo
- Tirzepatide
- $349/mo
- Coverage
- All 50 states
- Access
- Compounded
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Also on the scorecard
Sesame Care
B+An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
Check Sesame Care availabilitySeven telehealth sellers went through our checking bench in August 2026. None of them carries a WeighScore, a letter or a board position, and this one does not either. A grade on this site is a weighted number across six dimensions, and we do not publish a number we cannot defend on all six. What we can publish is what the checks turned up. The Edit — theedithealth.com, operated by The Edit Health LLC out of Austin, Texas — came out of that pass with the fewest internal contradictions of the seven.
Why this page has no grade on it
Every company on our provider reviews index has been through the full rubric in our methodology: cost value, dose and formulation, clinical oversight, labs and monitoring, fulfillment, contract terms. The Edit has been through the price and disclosure checks only. It is not on the board, it is not in the cheapest GLP-1 ledger, and nothing here should be read as a rank against a company that is. Treat this as the raw material a grade would be built from.
The rung we would file
Semaglutide is $209 per month and tirzepatide is $309 per month on the month-to-month rung — the standing recurring rate, no membership fee stacked on top, cancellable at the end of the current period.1 Prepay is a separate ladder: $575 once for three months of semaglutide, $1,065 once for six, $855 once for three months of tirzepatide, $1,575 once for six.1
Those prepay figures are labelled "billed once at the start of the plan", and the per-month numbers printed beside them are honest arithmetic — 575 over three months is $192, 1,065 over six is $178, 855 over three is $285, 1,575 over six is $263. It reads as faint praise until you have seen the alternative. The most common way a provider lands at the bottom of a cost board is a prepay total dressed up as a monthly rate, and this ladder does not do it. Our cost-value dimension exists to catch exactly that; see what compounded GLP-1 costs per month for the normalization we run before any figure goes on a board.
The advertised number is a promotion, not a rate
The Edit fronts semaglutide at $109 and tirzepatide at $209. That is $100 off a first order — one month, once. If you are budgeting six months of treatment, the numbers that matter are $209 and $309, or the prepay totals above. A first-month promo filed as a monthly price is one of the standard capture errors on our cost dimension, and it is the reason our boards rarely agree with a provider's own homepage.
The rest of the shelf
Beyond the two GLP-1 protocols, The Edit sells injectable NAD+ at $249 a month, injectable glutathione at $199, injectable sermorelin at $169, and a GHK-Cu topical cream at $129.1 There is no oral GLP-1 and no nasal line, so on dose and formulation this is a narrow menu — six protocols, five of them injectable. If route breadth is what you are shopping for, oral vs. injectable GLP-1 covers what you actually give up. The site also states in its own words that it does not sell research-use-only compounds, which is a more meaningful sentence than it looks in a market where an investigational shelf usually sits next to the prescription one.
Who signs the prescription, and who fills it
Clinical work runs through Arora Health & Aesthetics, LLC, whose medical director is Dr. Sean Arora. His NPI, 1841729449, resolves in the national registry to an active Family Medicine record in Seattle, Washington.2 Dispensing is attributed to The Pharmacy Hub, named on the site rather than described as an unnamed partner.
Naming a prescriber you can look up and naming the pharmacy that fills the vial are the two things our oversight and fulfillment dimensions reward most, and most of this cohort supplies neither. The Edit supplies both.
One caveat a reader shopping a shortlist needs: Trellis Vitality runs on the same medical group and the same medical director. Different pharmacy, different prices, genuinely different products — but putting both on a shortlist is not a second clinical opinion, and no board should imply that it is.
Contract terms, which is where good offers usually go bad
Getting started is free — the site states there is no charge and no card on file to begin, and a full refund if you are not approved. There is no membership fee, no minimum term and no prepay obligation unless you choose a prepay plan. Compounded medication is final sale once shipped, which is the category norm rather than a company quirk; is compounded semaglutide legit and safe? explains why that is how the framework works.
The Edit ships a complete Spanish mirror of its site — every page, 33 Spanish URLs in its own sitemap. That is rare enough to be worth stating plainly. Most operators translate one landing page and stop.
The regulatory screen, and why the zero counts
We queried the FDA's live warning-letter index in August 2026 for the company, its legal entity, its medical group and its named pharmacy. Nothing matched in the company column.3 That zero is only worth reporting because the same pass, run the same way, correctly returned a known letter dated February 2026 for an unrelated telehealth seller we used as a positive control. A broken query and a clean record return the identical empty result, so the control is what turns silence into evidence.
What we could not check
We could not reach a checkout price. The intake is questionnaire-gated and its scripts carry framework code rather than a price table, so everything above is the published ladder — corroborated across two independent surfaces on the provider's own site, which agreed exactly — and not a figure confirmed at the point of sale. That distinction is the difference between a filed price and a graded one, and it is the main reason this company sits off the board rather than on it.
What a grade would need
On price, The Edit is upper-quartile rather than cheap: Pepti at $99, Trellis Vitality at $150, Vyvron at $199 per four weeks and Auren Rx at $199 all undercut it on month-to-month semaglutide. What it brings instead is evidence — a named pharmacy, a prescriber NPI that verifies, and prepay arithmetic that divides correctly to the cent, which is the cleanest disclosure record of the seven we checked. A grade would still need the thing no marketing page can supply: an invoice at a maintenance dose confirming the standing rate is what actually recurs. If you want the standing question set to take to any of them, it is in our six-point checklist, and the weights behind every number on this site are in how the WeighScore is calculated.
Frequently asked questions
What does The Edit actually cost per month?
Semaglutide is $209 a month and tirzepatide is $309 a month on the standing month-to-month rung, as published on the provider's own product pages in August 2026. Prepay costs less per month: $575 once for three months of semaglutide, $1,065 once for six.
Is The Edit's $109 semaglutide price real?
It is a $100-off promotion on a first order, not a standing rate. The recurring price is $209 for semaglutide and $309 for tirzepatide. Budget on the recurring figure, because that is what you pay from month two onward.
Does The Edit have a WeighScore or a letter grade?
No. It has been through our price and disclosure checks but not the full six-dimension rubric, so it carries no score, no grade and no board position. This article publishes what the checks found, not a rank.
Who prescribes and who dispenses for The Edit?
Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director; his NPI, 1841729449, resolves to an active Family Medicine record in the national registry. Dispensing is attributed to The Pharmacy Hub, which the site names. Trellis Vitality uses the same medical group.
References
- The Edit Health LLC (2026). Products and pricing. theedithealth.com. https://theedithealth.com/products.html
- Centers for Medicare & Medicaid Services (2026). NPPES NPI Registry. npiregistry.cms.hhs.gov. https://npiregistry.cms.hhs.gov/
- U.S. Food and Drug Administration (2026). Warning Letters. FDA.gov — Compliance Actions and Activities. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Trellis Vitality, Checked but Not Graded: One Complete Ladder and Four Missing Ones
Trellis publishes the best-formed GLP-1 price table of the seven providers we checked in August 2026 — and four other programs with no ladder behind the number.
ReadLighter You, Checked but Not Graded: A Real Company With No Observable Price
Lighter You names four pharmacies with street addresses and publishes a $99 headline that matches no program on the site. Both things are true. August 2026.
ReadAuren Rx, Checked but Not Graded: Two Rungs on Every SKU, and No List of States
Auren Rx prints a subscribe price and a no-commitment price on every product — then never says which states it serves. Our August 2026 pass, in full.
ReadPepti, Checked but Not Graded: $99 Semaglutide and a Ladder That Renders Nowhere
Pepti prices semaglutide at $99 flat at every dose — while its own production data carries a $299-$449 per-dose ladder nothing renders. We could not settle it.
ReadVyvron, Checked but Not Graded: Thirteen Charges a Year, and No Monthly Tirzepatide
Vyvron prints prices per month and bills every four weeks — 13 charges a year — and its cheapest tirzepatide entry is $790 up front. August 2026 findings.
ReadRehydra+ Wellness, Checked but Not Graded: A $119 Membership With a $714 Floor
Every Rehydra+ GLP-1 membership is six months and explicitly non-cancelable, so its advertised monthly rates are really $714 to $2,514 commitments.
Read